SHANGHAI, Dec 17, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and ...

H2 Life, part of H2 Group KK, was celebrated for the Best Property Management Portfolio, recognising its excellent range of ...

The quantum era is no longer a distant future—it is unfolding now. Quranium’s Enterprise Quantum Readiness Survey highlights ...

MUMBAI, INDIA, Dec 16, 2024 - (ACN Newswire) - TAC InfoSec Limited (NSE Emerge: INE0SOY01013) (referred to hereafter as TAC ...

OVER 130 LEADING DEVELOPERS AND DESIGN PRACTICES FROM ACROSS ASIA GATHER IN BANGKOK FOR FINALE OF 2024 AWARDS SERIES, SEVEN ...

Under the terms of the agreement, BlackBerry will sell its Cylance assets to Arctic Wolf for $160 million of cash, subject to certain adjustments, and approximately 5.5 million common shares of Arctic ...

With Bitcoin, Dogecoin, and Litecoin now integrated, Bifrost Wallet users can manage these assets in preparation for FAssets - synthetic tokens backed by a robust on-chain collateral system, ...

The Citi PremierMiles Card is for frequent travellers who want to make every journey count. A miles credit card offers never-expiring miles on a range of purchases from travel expenses to rent and ...

作為雲頂新耀自身免疫性疾病領域的重磅產品，伊曲莫德於今年上半年陸續在中國澳門、新加坡獲得新藥上市批准，並於今年12月在中國澳門鏡湖醫院開出首張處方，正式開始惠及亞洲患者。此外，雲頂新耀也已在中國香港遞交了伊曲莫德的新藥上市許可申請並獲得正式受理。

上海, 2024年12月17日 - (亚太商讯) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国国家药品监督管理局已正式受理伊曲莫德（VELSIPITY (R)）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。伊曲莫德是一款每日一次口服的一线先进疗法，不仅使用方便、疗效佳，而且具有良好的安全性特征。

香港, 2024年12月16日 - (亚太商讯) - 近日，在第九届格隆汇"全球投资嘉年华 - 2025"盛会上，巨星传奇（06683.HK）凭借其在资本市场和业务领域的卓越表现，荣获"金格奖"年度卓越公司评选 - "年度投资价值奖（中小市值）"奖。

「金格獎」已連續頒發九屆，旨在篩選出最具投資參考價值的卓越公司榜單。其中，「年度投資價值獎」，重點發掘過去一年中展現出卓越投資價值和發展潛力的企業，基於上市公司營收以及淨利潤增長，以及公司規模、商業模式、管理能力、創新能力等多方面綜合考量，是對上市公 ...